# Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

> **NCT00189917** · PHASE1 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 60 (actual)

## Conditions studied

- Dermatitis, Atopic
- Hay Fever

## Interventions

- **BIOLOGICAL:** IMVAMUNE (MVA-BN)

## Key facts

- **NCT ID:** NCT00189917
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-12
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189917, "Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00189917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*